Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bortezomib (millennium pharmaceuticals).

Q Ping Dou1, Ronald H Goldfarb

  • 1Drug Discovery Program, H Lee Moffitt Cancer Center and Research Institute, MRC 1259C, 12902 Magnolia Drive, Tampa, FL 33612-9497, USA. douqp@moffitt.usf.edu

Idrugs : the Investigational Drugs Journal
|June 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects.

Biomolecules·2025
Same author

Metastatic Lymph Node 64 (MLN64) Expression in Gastric Cancer: The Clinical and Molecular Implications in Drug Resistance.

Cancer genomics & proteomics·2023
Same author

Striatins and STRIPAK complex partners in clinical outcomes of patients with breast cancer and responses to drug treatment.

Chinese journal of cancer research = Chung-kuo yen cheng yen chiu·2023
Same author

Claudin-10 in the Blood Brain Barrier Function of Cerebral Endothelial Cells and Transendothelial Invasion of Breast Cancer Cells.

Anticancer research·2023
Same author

Activated Leukocyte Cell Adhesion Molecule (ALCAM), a Potential 'Seed' and 'Soil' Receptor in the Peritoneal Metastasis of Gastrointestinal Cancers.

International journal of molecular sciences·2023
Same author

Death associated protein‑3 (DAP3) and DAP3 binding cell death enhancer‑1 (DELE1) in human colorectal cancer, and their impacts on clinical outcome and chemoresistance.

International journal of oncology·2022

Bortezomib, a proteasome inhibitor, is being evaluated for various cancers. Clinical trials are underway for multiple myeloma, chronic lymphocytic leukemia, and solid tumors.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Bortezomib is a novel ubiquitin proteasome inhibitor.
  • Millennium Pharmaceuticals is developing bortezomib for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of bortezomib in clinical trials.
  • To assess bortezomib's potential in treating multiple myeloma, chronic lymphocytic leukemia, and solid tumors.

Main Methods:

  • Phase I, II, and III clinical trials were initiated for various cancers.
  • Combination studies were conducted for solid tumors including prostate, pancreatic, and colorectal carcinoma.

Main Results:

  • Bortezomib is under investigation for multiple myeloma and chronic lymphocytic leukemia.
  • The drug is in trials for various solid tumors, with Fast Track status granted by the FDA.

Related Experiment Videos

Conclusions:

  • Bortezomib shows promise as a treatment for multiple myeloma and other cancers.
  • Ongoing pivotal phase III trials will further determine bortezomib's therapeutic value.